Whilst genomic profiling of patient samples in this study demonstrated a low frequency of mutations in DDR PARP and key HR genes, a third of the HR mutations identified are currently being therapeutically exploited by PARPi in other cancer types, suggesting that GI cancer patients with these mutations could potentially benefit from PARPi. This evidence concerns the gene PARP1 and cancer.